Skip to main content
Quest Diagnostics

Cardiometabolic Disease–Associated Markers Begin to Increase at an A1C >5%

Cardiometabolic Disease–Associated Markers Begin to Increase at an A1C >5%

Authors: Penn MS, Winchester TB, Saghir J, Koney A, Latsko MS, Dixit SB, Eckel RH, Saghir M

Citation: AACE Endocrinol Diabetes. 2026 Aug 10. doi:10.1016/j.aed.2026.07.019. Online ahead of print.

Specialties: Cardiology, Cardiovascular disease, Endocrinology

Disclaimer: One or more of the authors of this publication were employed at the time by Cleveland HeartLab, a subsidiary of Quest Diagnostics

Related content

On-Demand Webinar
Utilizing Apolipoprotein B in Cardiovascular Risk Assessment
Audio Podcast
Instant Insights: Apolipoprotein B
Publication
An HDL Proteomic Score Independently Predicts Incident Atherosclerotic Cardiovascular Disease
Audio Podcast
The Cardiometabolic Approach: A Solution to Modern Disease Risk Assessment
Test FAQ
LDL Cholesterol Calculations
Audio Podcast
Instant Insight: Metabolic Risk Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.